Community Health Center Drug Pricing Protection Act

Legislative bill overview

HR 7391 amends the Public Health Service Act to prevent Federally-qualified health centers (FQHCs) from being charged prices higher than the 340B ceiling price when purchasing covered outpatient drugs. The 340B program is a federal discount program that requires pharmaceutical manufacturers to provide significant discounts on medications to eligible healthcare entities. This bill specifically protects FQHCs from paying above-ceiling prices at the point of purchase.

Why is this important

FQHCs serve uninsured, underinsured, and low-income patients across rural and urban areas. Drug pricing directly affects the affordability of care these centers can provide and their operational sustainability. By locking in ceiling prices at purchase, the bill aims to ensure FQHCs receive the full intended benefit of the 340B program, potentially reducing medication costs for vulnerable patient populations and preventing middlemen from capturing program savings.

Potential points of contention

• Pharmaceutical manufacturer concerns: Drug makers may argue the provision increases regulatory burden and limits their pricing flexibility, potentially affecting profit margins
• Intermediary impact: Drug wholesalers and pharmacy benefit managers (PBMs) who currently benefit from pricing gaps between ceiling and retail prices would lose revenue under stricter enforcement
• Implementation logistics: Questions remain about enforcement mechanisms, what constitutes violation, and how FQHCs would verify compliance at point of purchase across different drug distribution channels